RB.L - Reckitt Benckiser Group plc

LSE - LSE Delayed Price. Currency in GBp
7,512.00
+74.00 (+0.99%)
As of 9:28AM BST. Market open.
Stock chart is not supported by your current browser
Previous close7,438.00
Open7,450.00
Bid7,512.00 x 0
Ask7,512.00 x 0
Day's range7,446.00 - 7,518.00
52-week range5,130.00 - 8,191.30
Volume87,277
Avg. volume1,460,484
Market cap53.418B
Beta (5Y monthly)0.25
PE ratio (TTM)N/A
EPS (TTM)-519.70
Earnings date28 Jul 2020
Forward dividend & yield2.03 (2.73%)
Ex-dividend date16 Apr 2020
1y target est7,085.56
  • U.S. EPA approves use of Lysol Disinfectant Spray against COVID-19
    Reuters

    U.S. EPA approves use of Lysol Disinfectant Spray against COVID-19

    The U.S. EPA said in a statement that the agency had approved two products, Lysol Disinfectant Spray and Lysol Disinfectant Max Cover Mist, based on laboratory testing that showed the products were effective against COVID-19. Reckitt Benckiser reported record sales growth in the first quarter and predicted a stronger-than-expected performance in 2020 as customers stocked up on Lysol disinfectants, Mucinex cough syrup and Dettol soap ahead of the coronavirus lockdowns. "Lysol is currently testing the efficacy of other disinfectant products in the brand portfolio," Ferran Rousaud, marketing director for Lysol, said in a statement.

  • 'This is where the future is going:’ Amazon exec on $2 billion Climate Pledge Fund
    Yahoo Finance

    'This is where the future is going:’ Amazon exec on $2 billion Climate Pledge Fund

    Amazon launched a $2 billion venture capital fund Tuesday to invest in technologies and services aimed at reducing greenhouse gas emissions. Speaking to Yahoo Finance, Amazon’s Head of Worldwide Sustainability Kara Hurst said the move was yet another step to use the e-commerce giant’s 'scale for good' as it sets aggressive targets to become carbon neutral by 2040.  

  • The Zacks Analyst Blog Highlights: Reckitt Benckiser, Henkel AG, DexCom, Tencent and Peloton Interactive
    Zacks

    The Zacks Analyst Blog Highlights: Reckitt Benckiser, Henkel AG, DexCom, Tencent and Peloton Interactive

    The Zacks Analyst Blog Highlights: Reckitt Benckiser, Henkel AG, DexCom, Tencent and Peloton Interactive

  • The Zacks Analyst Blog Highlights: Tencent, Abbvie and Reckitt Benckiser
    Zacks

    The Zacks Analyst Blog Highlights: Tencent, Abbvie and Reckitt Benckiser

    The Zacks Analyst Blog Highlights: Tencent, Abbvie and Reckitt Benckiser

  • Reckitt Benckiser's sales hit record on coronavirus disinfectant boom
    Reuters

    Reckitt Benckiser's sales hit record on coronavirus disinfectant boom

    In February, Reckitt had announced plans to spend 2 billion pounds over the next three years to spur growth. Reckitt said its business was more resilient now than a few months ago and it was adjusting quickly to a world where personal hygiene was becoming more important. Laxman Narasimhan, who joined as CEO in September, said that he expected more pronounced changes in consumer behaviour the longer people are forced to sit at home.

  • Coronavirus update: US death toll tops 50K as Trump stirs debate over treatments, reopenings
    Yahoo Finance

    Coronavirus update: US death toll tops 50K as Trump stirs debate over treatments, reopenings

    The U.S. death toll and COVID-19 cases climbed, as arguments flared over coronavirus treatments and the path to restarting the economy.

  • Lysol maker urges people not to inject disinfectants after Trump remarks
    Reuters

    Lysol maker urges people not to inject disinfectants after Trump remarks

    "Under no circumstance should our disinfectant products be administered into the human body (through injection, ingestion or any other route)," the company said. Trump said researchers should try to apply their findings to coronavirus patients by inserting light or disinfectant into their bodies. Reckitt said due to recent speculation and social media activity, it had been asked whether internal usage of disinfectants may be appropriate for investigation or use as a treatment for coronavirus.

  • Trump's coronavirus disinfectant comments "dangerous", doctors say
    Reuters

    Trump's coronavirus disinfectant comments "dangerous", doctors say

    Doctors and health experts urged people not to drink or inject disinfectant on Friday after U.S. President Donald Trump suggested scientists should investigate inserting the cleaning agent into the body as a way to cure COVID-19. "You may not die of COVID-19 after injecting disinfectant, but only because you may already be dead from the injection." Trump said at his daily media briefing on Thursday that scientists should explore whether inserting light or disinfectant into the bodies of people infected with the new coronavirus might help them clear the disease.

  • Reuters

    UK investors tell companies to rethink bonuses if scrapping dividends

    Britain's investment managers would expect banks and other companies to rethink bonuses if they are scrapping payouts to shareholders, the Investment Association said on Wednesday. Top UK banks have scrapped dividends for 2019 and interim dividends for 2020 after being asked to do so by the Bank of England, with other firms also stopping payouts as the economy remains in lockdown. The current situation should, however, not be used to "rebase or reduce" dividends unneccesarily, IA Chief Executive Chris Cummings said in a statement.

  • Reuters

    No evidence ibuprofen bad for COVID-19 patients - Nurofen-maker

    The company's statement followed a warning https://www.reuters.com/article/us-health-coronavirus-france-drug/france-warns-against-use-of-anti-inflammatory-drugs-to-tackle-coronavirus-idUSKBN2110Q8 by France's health minister on Saturday that people should not use anti-inflammatory drugs such as ibuprofen if they have coronavirus-like symptoms. Nurofen, one of Reckitt's more popular drugs, contains 200 mg of Ibuprofen as its active ingredient in each tablet and is indicated for "effective pain and inflammation relief and reducing fever," according to the company's website.

  • Cleaning product makers race to labs to bolster coronavirus claims
    Reuters

    Cleaning product makers race to labs to bolster coronavirus claims

    The maker of Lysol and Dettol disinfectants said it has already obtained a strain of the novel coronavirus, known as SARS-CoV-2, from an independent lab and plans to use the strain to test whether its products kill the virus. In 2012, for instance, when MERS-coronavirus was a major public health concern, cleaning products had to prove they could kill 9,999 out of 10,000 MERS-Coronavirus cells, according to the agencies’ requirement. COVID-19, the disease caused by novel coronavirus, originated in Wuhan, China, and has spread to more than 100 countries across the world.

  • Reckitt to spend 2 billion pounds on growth after big writedown
    Reuters

    Reckitt to spend 2 billion pounds on growth after big writedown

    The British maker of Dettol antiseptic and Strepsils lozenges reported like-for-like 2019 sales growth of 0.8% in line with guidance but that lagged peers such as Procter & Gamble which are targeting 3-5% expansion. Reckitt bought Mead Johnson for about $17 billion in 2017 to expand in developing markets, especially China. Its writedown on the business meant a 3.7 billion net loss for 2019.

  • Reckitt takes short term pain for long term growth
    Reuters

    Reckitt takes short term pain for long term growth

    The British maker of Durex condoms and Strepsils lozenges reported like-for-like 2019 sales growth of 0.8%, in line with guidance but lagging peers including Procter & Gamble <PG.N> which is targeting underlying growth of 3-5%. Reckitt bought Mead Johnson for about 13 billion pounds in 2017, betting on the rising demand for branded baby formula products in developing markets, especially China.

  • Britain's Reckitt Benckiser gives new parents more paid leave
    Reuters

    Britain's Reckitt Benckiser gives new parents more paid leave

    Mothers will also have the option to take a further six months of leave without pay. The Durex condom and Lysol disinfectant maker also said it would increase paid paternity leave for fathers and partners to four weeks, with the option to take a further four weeks of leave without pay. Reckitt Benckiser has also launched suites for breastfeeding mothers returning to work and free breast pumps if needed.

  • Reckitt Benckiser gives new parents more paid leave
    Reuters

    Reckitt Benckiser gives new parents more paid leave

    Mothers will also have the option to take a further six months of leave without pay. The Durex condom and Lysol disinfectant maker also said it would increase paid paternity leave for fathers and partners to four weeks, with the option to take a further four weeks of leave without pay. Reckitt Benckiser has also launched suites for breastfeeding mothers returning to work and free breast pumps if needed.

  • Reuters

    New York, states reach $700 million settlement with Reckitt over opioid probes

    The deal is a part of an up to $1.4 billion settlement agreed to in July to resolve U.S. state and federal claims that Reckitt Benckiser's former pharmaceuticals business Indivior, before it was spun out, carried out an illegal scheme to boost sales of opioid addiction treatment Suboxone.

  • Exporters lift FTSE as pound slips on Brexit fatigue
    Reuters

    Exporters lift FTSE as pound slips on Brexit fatigue

    The FTSE 100 added 0.7%, with BP and Shell both gaining more than 2% and Asia-focussed HSBC also rising after China signalled progress in trade talks with the United States. Other standouts in the index, whose components book most of their earnings abroad, were AstraZeneca and BAT, while Durex condom maker Reckitt pared losses despite cutting its sales view for the second time this year. British Prime Minister Boris Johnson told parliament that if it delayed his legislation to leave the European Union he would abandon his attempt to ratify the deal and push for an election instead, threatening further political turmoil.

  • New CEO vows improvements as Reckitt cuts sales forecast again
    Reuters

    New CEO vows improvements as Reckitt cuts sales forecast again

    Reckitt Benckiser's <RB.L> new chief executive promised on Tuesday to step up spending on its brands and improve performance after the British household goods maker cut its full-year sales forecast for a second time. "We are not pleased with where we are and we must consistently deliver," Laxman Narasimhan, who took over from long-time CEO Rakesh Kapoor in September, said on his first call with the investment community. Narasimhan particularly lamented the performance of the firm's Health business, its largest, where a failed product launch, the nearly $17 billion acquisition of Mead Johnson, and a temporary baby milk factory shutdown in the Netherlands, have all caused significant disruption, some lasting to this day.

  • Reckitt hires Ahold's Carr to take over as CFO in 2020
    Reuters

    Reckitt hires Ahold's Carr to take over as CFO in 2020

    The maker of Durex condoms and Lysol disinfectant said on Monday that Carr, who has been finance chief at Dutch-American supermarket operator Ahold since 2011, would bring "extensive experience across consumer and retail companies". The appointment of Carr, who worked for Reckitt between 1994 and 2004, is its second big management change this year after replacing long-time chief executive Rakesh Kapoor with PepsiCo <PEP.O> executive Laxman Narasimhan as CEO.

  • Trade worries hit FTSE 100, banks slip on BoE plan
    Reuters

    Trade worries hit FTSE 100, banks slip on BoE plan

    The blue-chip index followed Wall Street lower after U.S. President Donald Trump warned China not to wait for the 2020 U.S. presidential election to make a trade deal. Big British banks, such as Barclays <BARC.L> and RBS <RBS.L>, fell after the BoE said banks would have to tell investors in 2021 if they could be closed down without disrupting financial markets. Corporate earnings were the main drivers behind most of the major stock moves on both UK indexes.

  • Reckitt cuts sales target as China infant formula demand slows
    Reuters

    Reckitt cuts sales target as China infant formula demand slows

    Reckitt Benckiser <RB.L> cut its full-year revenue target after reporting lower than expected sales in its last quarter under long-time chief executive Rakesh Kapoor, hurt by a surprise slowdown in demand for infant formula in China. The Durex condom and Lysol disinfectant maker said on Tuesday it now expected full-year like-for-like sales growth of between 2% and 3%, down from its previous target of 3% to 4%, also blaming a tough market in Europe for its downgrade. Reckitt, which kept its "broadly flat" operating margin target, said slowing birth rates over the past two years and increased competition had led to market share losses for its Enfamil infant nutrition products in China, its biggest market for baby food.

  • Bayer sells Dr. Scholl's footcare brand to Yellow Wood Partners
    Reuters

    Bayer sells Dr. Scholl's footcare brand to Yellow Wood Partners

    Germany's Bayer <BAYGn.DE> signed a deal on Monday to sell its Dr. Scholl's footcare brand to U.S. private investment firm Yellow Wood Partners for $585 million (£469.31 million), the second of two consumer care products it had put on the block. Bayer, whose stock has slumped amid lawsuits over an alleged cancer-causing effect of its Roundup weed killer, struck a deal in May to sell U.S. sun care brand Coppertone to Nivea maker Beiersdorf <BEIG.DE> for $550 million. The divestments are part of a wider overhaul unveiled in November by Bayer Chief Executive Werner Baumann, who is under pressure to boost the share price.

  • Associated Press

    Reckitt Benckiser pays $1.4 billion in opioid settlement

    Consumer products company Reckitt Benckiser says it will pay $1.4 billion to resolve U.S. investigations into the marketing of an anti-addiction drug by a subsidiary. The company said Thursday it reached agreements with the U.S. Department of Justice and the Federal Trade Commission. The government alleged that an ex-Reckitt subsidiary sought to increase prescriptions for Suboxone Film by deceiving health care providers into believing the drug was safer than other opioid addiction treatments.

  • FTSE 100 drops as healthcare giants overshadow Fed-driven rally
    Reuters

    FTSE 100 drops as healthcare giants overshadow Fed-driven rally

    The FTSE 100 <.FTSE> shed 0.3%, while the mid-cap FTSE 250 <.FTMC> capitalised on a rise in sterling to add 0.1%. The U.S. government scrapped one of its most ambitious proposals for lowering prescription medicine prices, backing down from a policy that would have required health insurers to pass on billions of dollars in rebates they receive from drugmakers to Medicare patients. "Overall, we view this outcome as a modest negative for the major pharmaceutical group," JP Morgan analysts wrote, adding that the move had removed a "potential positive catalyst" for the sector.

  • Reckitt to pay $1.4 billion to end U.S. opioid addiction treatment probes
    Reuters

    Reckitt to pay $1.4 billion to end U.S. opioid addiction treatment probes

    The settlement, the largest by any company related to the U.S. opioid epidemic, resolved long-running probes by the U.S. Justice Department and the Federal Trade Commission into the companies' marketing and sales of Suboxone Film. The deal came after Indivior in April was indicted and accused of deceiving doctors and healthcare benefit programs into believing Suboxone Film, itself a form of opioid, was safer and less susceptible to abuse than similar drugs.